Broadly, the purpose of this project is to evaluate the baseline stroke and dementia risk of those Indvidual identified by NLP and characterize the population identified during the recruitment process through enrollment. Additionally, we seek to assess changes to medical care and medications in the 90-days after being informed of the NLP findings.
The goal of this protocol is to validate a non-contact technology with miniaturized radar integrated with a visible camera in a high-risk neonatal population to ultimately provide a safe alternative to current standard contact vital sign monitoring systems.
we plan to use non invasive ADP (air displacement plethysmography) method to measure body composition in very low birth weight infants and follow their neurodevelopment using HINE (Hammersmith Infant Neurological examination)
Aortic stenosis (AS) affects over 12.6 million adults and causes an estimated 102,700 deaths annually. There is interest in novel approaches to identify valve disease earlier the disease course before symptoms occur. We previously used machine learning (ML) to develop a system for fully automated AS screening. Here we are validating the performance of this new method for identifying AS.
This will be a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of PLS240 in eligible participants with ESKD and SHPT.
The primary goal of this study is to improve our understanding of changes in skeletal muscle mass in the arms and the legs during a hospitalization for advanced HF. We plan to measure muscle thickness with an ultrasound machine in two locations on the body (the outer thigh and the upper arm muscle, of the dominant side) from the time a patient is first admitted to the ICU with HF as well as before and after any surgical HF therapies.
REACH is a program to energize and empower people living with lupus through movement. The REACH Lupus study is a randomized controlled pilot study to evaluate the REACH program.
